228 related articles for article (PubMed ID: 27347635)
1. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
2. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
3. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
5. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
6. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
[TBL] [Abstract][Full Text] [Related]
7. Endocrine profiling and prioritization of environmental chemicals using ToxCast data.
Reif DM; Martin MT; Tan SW; Houck KA; Judson RS; Richard AM; Knudsen TB; Dix DJ; Kavlock RJ
Environ Health Perspect; 2010 Dec; 118(12):1714-20. PubMed ID: 20826373
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
9. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
10. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
[TBL] [Abstract][Full Text] [Related]
11. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
12. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
13. Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models.
Nelms MD; Antonijevic T; Ring C; Harris DL; Bever RJ; Lynn SG; Williams D; Chappell G; Boyles R; Borghoff S; Edwards SW; Markey K
Front Toxicol; 2024; 6():1346767. PubMed ID: 38694816
[TBL] [Abstract][Full Text] [Related]
14. Toxicity testing and endocrine disrupting chemicals.
Vandenberg LN
Adv Pharmacol; 2021; 92():35-71. PubMed ID: 34452691
[TBL] [Abstract][Full Text] [Related]
15. Toxicity profiles in mice treated with hepatotumorigenic and non-hepatotumorigenic triazole conazole fungicides: Propiconazole, triadimefon, and myclobutanil.
Allen JW; Wolf DC; George MH; Hester SD; Sun G; Thai SF; Delker DA; Moore T; Jones C; Nelson G; Roop BC; Leavitt S; Winkfield E; Ward WO; Nesnow S
Toxicol Pathol; 2006; 34(7):853-62. PubMed ID: 17178687
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
17. Development of an In Vitro Human Thyroid Microtissue Model for Chemical Screening.
Deisenroth C; Soldatow VY; Ford J; Stewart W; Brinkman C; LeCluyse EL; MacMillan DK; Thomas RS
Toxicol Sci; 2020 Mar; 174(1):63-78. PubMed ID: 31808822
[TBL] [Abstract][Full Text] [Related]
18. Review and analysis of the potential for glyphosate to interact with the estrogen, androgen and thyroid pathways.
Levine SL; Webb EG; Saltmiras DA
Pest Manag Sci; 2020 Sep; 76(9):2886-2906. PubMed ID: 32608552
[TBL] [Abstract][Full Text] [Related]
19. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional profiles in liver from rats treated with tumorigenic and non-tumorigenic triazole conazole fungicides: Propiconazole, triadimefon, and myclobutanil.
Hester SD; Wolf DC; Nesnow S; Thai SF
Toxicol Pathol; 2006; 34(7):879-94. PubMed ID: 17178689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
